These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18686126)

  • 1. The effect of circulation lifetime and drug-to-lipid ratio of intravenously administered lipid nanoparticles on the biodistribution and immunostimulatory activity of encapsulated CpG-ODN.
    Raney SG; Wilson KD; Sekirov L; Chikh G; de Jong SD; Cullis PR; Tam YK
    J Drug Target; 2008 Aug; 16(7):564-77. PubMed ID: 18686126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles.
    Wilson KD; Raney SG; Sekirov L; Chikh G; deJong SD; Cullis PR; Tam YK
    Int Immunopharmacol; 2007 Aug; 7(8):1064-75. PubMed ID: 17570323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy.
    Wilson KD; de Jong SD; Tam YK
    Adv Drug Deliv Rev; 2009 Mar; 61(3):233-42. PubMed ID: 19232375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of stabilized plasmid lipid particles and lipid nanoparticle encapsulated CpG containing oligodeoxynucleotides as a systemic genetic vaccine.
    Wilson KD; de Jong SD; Kazem M; Lall R; Hope MJ; Cullis PR; Tam YK
    J Gene Med; 2009 Jan; 11(1):14-25. PubMed ID: 19003796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.
    Chikh G; de Jong SD; Sekirov L; Raney SG; Kazem M; Wilson KD; Cullis PR; Dutz JP; Tam YK
    Int Immunol; 2009 Jul; 21(7):757-67. PubMed ID: 19502586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles.
    Mui B; Raney SG; Semple SC; Hope MJ
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1185-92. PubMed ID: 11504819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif.
    Zhang Z; Guo K; Schluesener HJ
    J Neuroimmunol; 2005 Apr; 161(1-2):68-77. PubMed ID: 15748945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides.
    Mutwiri GK; Nichani AK; Babiuk S; Babiuk LA
    J Control Release; 2004 May; 97(1):1-17. PubMed ID: 15147800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
    de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
    Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid.
    Semple SC; Harasym TO; Clow KA; Ansell SM; Klimuk SK; Hope MJ
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1020-6. PubMed ID: 15525796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model.
    Hamzah J; Altin JG; Herringson T; Parish CR; Hämmerling GJ; O'Donoghue H; Ganss R
    J Immunol; 2009 Jul; 183(2):1091-8. PubMed ID: 19561111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration.
    Noll BO; McCluskie MJ; Sniatala T; Lohner A; Yuill S; Krieg AM; Schetter C; Davis HL; Uhlmann E
    Biochem Pharmacol; 2005 Mar; 69(6):981-91. PubMed ID: 15748709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake, intracellular distribution, and novel binding proteins of immunostimulatory CpG oligodeoxynucleotides in microglial cells.
    Zhang Z; Weinschenk T; Schluesener HJ
    J Neuroimmunol; 2005 Mar; 160(1-2):32-40. PubMed ID: 15710455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of mucosal immune responses by intranasal co-delivery of Newcastle disease vaccine plus CpG oligonucleotide in SPF chickens in vivo.
    Zhang L; Zhang M; Li J; Cao T; Tian X; Zhou F
    Res Vet Sci; 2008 Dec; 85(3):495-502. PubMed ID: 18359498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory consequences of ODN CpG-polycation complexes.
    Partidos CD; Hoebeke J; Wieckowski S; Chaloin O; Bianco A; Moreau E; Briand JP; Desgranges C; Muller S
    Methods; 2009 Dec; 49(4):328-33. PubMed ID: 19303048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo immunostimulatory effects of CpG ODN in newborn piglets.
    Linghua Z; Xingshan T; Fengzhen Z
    Mol Immunol; 2007 Feb; 44(6):1238-44. PubMed ID: 16908068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by 4-aminoquinolines and other weak bases: mechanistic studies.
    Manzel L; Strekowski L; Ismail FM; Smith JC; Macfarlane DE
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1337-47. PubMed ID: 10565859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha 2-macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism.
    Anderson RB; Cianciolo GJ; Kennedy MN; Pizzo SV
    J Leukoc Biol; 2008 Feb; 83(2):381-92. PubMed ID: 17967834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides.
    Mutwiri G; van Drunen Littel-van den Hurk S; Babiuk LA
    Adv Drug Deliv Rev; 2009 Mar; 61(3):226-32. PubMed ID: 19162103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved systemic pharmacokinetics, biodistribution, and antitumor activity of CpG oligodeoxynucleotides complexed to endogenous antibodies in vivo.
    Palma E; Cho MJ
    J Control Release; 2007 Jul; 120(1-2):95-103. PubMed ID: 17509715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.